Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy.
Gleason pattern 4/5
Prostate cancer
Recurrence risk
Tumor volume
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
14
04
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
The risk of prostate cancer metastatic is correlated with its volume and grade. These parameters are now best estimated preoperatively with magnetic resonance imaging (MRI) and MRI-guided biopsy. To estimate the risk of metastatic recurrence after radical prostatectomy (RP) in our model versus conventional clinical European Association of Urology (EAU) classification. The secondary objective is biochemical recurrence (BCR). A retrospective study was conducted of a cohort of 713 patients having undergone MRI-guided biopsies and RP between 2009 and 2018. The preoperative variables included prostate-specific antigen, cT stage, tumor volume (TV) based on the lesion's largest diameter at MRI, percentage of Gleason pattern 4/5 (%GP4/5) at MRI-guided biopsy, and volume of GP4/5 (VolGP4/5) calculated as TV × %GP4/5. The variables' ability to predict recurrence was determined in univariable and multivariable Fine-and-Gray models, according to the Akaike information criterion (AIC) and Harrell's C-index. Overall, 176 (25%), 430 (60%), and 107 (15%) patients had low, intermediate, and high-risk disease, respectively, according to the EAU classification. During a median follow-up period of 57 mo, metastatic recurrence was observed in 48 patients with a 5-yr probability of 5.6% (95% confidence interval [CI] 3.9-7.7). VolGP4/5 (categories: <0.5, 0.5-1.0, 1.01-3.2, and >3.2 ml) was the parameter with the lowest AIC and the highest C-index for metastatic recurrence of 0.82 (95% CI 0.76-0.88), and for BCR it was 0.73 (95% CI 0.68-0.78). In a multivariable model that included %GP4/5 and TV, C-index values were 0.86 (95% CI 0.79-0.91) for metastatic recurrence and 0.77 (0.72-0.82) for BCR. The same results for EAU classification were 0.74 (0.67-0.80) and 0.67 (0.63-0.72), respectively. Limitations are related to short follow-up and expertise of radiologists and urologists. We developed a preoperative risk tool integrating the VolGP4/5 based on MRI and MRI-guided biopsies to predict metastatic recurrence after RP. Our model showed higher accuracy than conventional clinical risk models. These findings might enable physicians to provide more personalized patient care. Aggressiveness of prostate cancer evaluated before treatment by incorporating magnetic resonance imaging (MRI) and MRI-guided biopsy results gives a better estimate of the risk of metastatic recurrence than previous parameters not based on MRI.
Sections du résumé
Background
UNASSIGNED
The risk of prostate cancer metastatic is correlated with its volume and grade. These parameters are now best estimated preoperatively with magnetic resonance imaging (MRI) and MRI-guided biopsy.
Objective
UNASSIGNED
To estimate the risk of metastatic recurrence after radical prostatectomy (RP) in our model versus conventional clinical European Association of Urology (EAU) classification. The secondary objective is biochemical recurrence (BCR).
Design setting and participants
UNASSIGNED
A retrospective study was conducted of a cohort of 713 patients having undergone MRI-guided biopsies and RP between 2009 and 2018. The preoperative variables included prostate-specific antigen, cT stage, tumor volume (TV) based on the lesion's largest diameter at MRI, percentage of Gleason pattern 4/5 (%GP4/5) at MRI-guided biopsy, and volume of GP4/5 (VolGP4/5) calculated as TV × %GP4/5.
Outcome measurements and statistical analysis
UNASSIGNED
The variables' ability to predict recurrence was determined in univariable and multivariable Fine-and-Gray models, according to the Akaike information criterion (AIC) and Harrell's C-index.
Results and limitations
UNASSIGNED
Overall, 176 (25%), 430 (60%), and 107 (15%) patients had low, intermediate, and high-risk disease, respectively, according to the EAU classification. During a median follow-up period of 57 mo, metastatic recurrence was observed in 48 patients with a 5-yr probability of 5.6% (95% confidence interval [CI] 3.9-7.7). VolGP4/5 (categories: <0.5, 0.5-1.0, 1.01-3.2, and >3.2 ml) was the parameter with the lowest AIC and the highest C-index for metastatic recurrence of 0.82 (95% CI 0.76-0.88), and for BCR it was 0.73 (95% CI 0.68-0.78). In a multivariable model that included %GP4/5 and TV, C-index values were 0.86 (95% CI 0.79-0.91) for metastatic recurrence and 0.77 (0.72-0.82) for BCR. The same results for EAU classification were 0.74 (0.67-0.80) and 0.67 (0.63-0.72), respectively. Limitations are related to short follow-up and expertise of radiologists and urologists.
Conclusions
UNASSIGNED
We developed a preoperative risk tool integrating the VolGP4/5 based on MRI and MRI-guided biopsies to predict metastatic recurrence after RP. Our model showed higher accuracy than conventional clinical risk models. These findings might enable physicians to provide more personalized patient care.
Patient summary
UNASSIGNED
Aggressiveness of prostate cancer evaluated before treatment by incorporating magnetic resonance imaging (MRI) and MRI-guided biopsy results gives a better estimate of the risk of metastatic recurrence than previous parameters not based on MRI.
Identifiants
pubmed: 35813259
doi: 10.1016/j.euros.2022.04.011
pii: S2666-1683(22)00586-9
pmc: PMC9257652
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24-34Informations de copyright
© 2022 The Author(s).
Références
Epidemiology. 2009 Jul;20(4):555-61
pubmed: 19367167
J Urol. 2019 Dec;202(6):1182-1187
pubmed: 31246548
Eur Urol. 2017 Feb;71(2):301
pubmed: 27687819
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Eur Urol. 2021 Jan;79(1):3-5
pubmed: 33189461
J Urol. 2021 Feb;205(2):444-451
pubmed: 33026934
BMJ. 2009 Mar 31;338:b604
pubmed: 19336487
BJU Int. 2019 Aug;124(2):275-281
pubmed: 30694605
Am J Surg Pathol. 2016 Oct;40(10):1400-6
pubmed: 27379821
J Urol. 2021 Apr;205(4):1055-1062
pubmed: 33207133
Eur Urol. 2020 Aug;78(2):138-142
pubmed: 32268944
Eur Urol Oncol. 2020 Dec;3(6):739-747
pubmed: 32847747
Prostate. 2022 Apr;82(5):566-575
pubmed: 35067945
Eur Urol. 2012 Aug;62(2):204-9
pubmed: 22541389
World J Urol. 2020 Oct;38(10):2493-2500
pubmed: 31838560
Eur Urol. 2016 Apr;69(4):592-598
pubmed: 26542947
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Eur Urol. 2022 Feb;81(2):193-203
pubmed: 34399996
J Clin Oncol. 2005 May 1;23(13):2911-7
pubmed: 15860849
Eur Urol. 2016 Apr;69(4):557-560
pubmed: 26563871
J Clin Oncol. 2017 Sep 20;35(27):3097-3104
pubmed: 28796587
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Eur Urol. 2019 Sep;76(3):284-303
pubmed: 31130434
J Urol. 2016 Aug;196(2):405-11
pubmed: 26920466
J Urol. 2021 Jul;206(1):80-87
pubmed: 33683939
Biometrics. 1978 Dec;34(4):541-54
pubmed: 373811
Cancer. 1990 Sep 15;66(6):1225-33
pubmed: 2400973
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566